The most innovative companies in diabetes
Diabetes affects a startling number of people worldwide -- some 415 million in 2015, with 44.3 million of those in North America. About a third of people with diabetes do not know they have it.
Last year Quid kicked off a new series focusing on Type 2 diabetes (which accounts for nearly 95% of the world’s cases), including an analysis of 40,000 patient posts from a leading diabetes forum.
Still, we wanted to take a closer look at the disease, specifically at innovative companies treating diabetes.
First we looked in our proprietary company database of 50,000 startups to see which are receiving the largest VC investments and for what.
We identified more than 1,300 companies playing in the diabetes landscape. In the network above, 9.6% of companies focus on research and drug discovery, with a whopping $2.9 billion in investment in this area.
And even though it includes fewer companies and makes up a much smaller portion of the network, clinical trial-stage drug manufacturers pulled in the next-highest investment figure, roughly $2 billion in total since 2012. Next, companies in glucose monitoring, diagnostics, and immune-based therapies make up a significant portion of the network and account for a huge chunk of the funds raised.
One cluster was particularly interesting in this map: startups in the biotech, small molecules and drug delivery cluster account for just 2.7% of the network but pulled in relatively high investment dollars, topping $955 million.
Zooming in, we see that companies in this cluster produce very interesting technologies indeed.
Delpor, for example, man Continue reading